Abstracts tagged "autoimmune diseases"

Abstract Number: 0087 • ACR Convergence 2024
SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion
Ethan Jung¹, Marie semana¹, Ivan Cheng¹, Helena Silva¹, Sandro Vivona¹, Somya Singh¹, Michele Bauer¹, Mohammed Ali¹, Henry Rosas¹, Woei Chang¹, Deepti Rokkam¹, Patrick Lupardus¹, Martin Oft¹ and Paul-Joseph Aspuria², ¹Synthekine, Menlo Park, ²Sythekine, Menlo Park, CA
Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
Abstract Number: 0244 • ACR Convergence 2024
Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series
Pei-Hsinq Lai¹, Cheng-Hsun Lu² and Song-Chou Hsieh³, ¹Taipei City Hospital, Taipei, Taiwan (Republic of China), ²National Taiwan University Hospital, Taipei, Taiwan, ³National Taiwan University Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: Post-COVID interstitial lung disease (post-COVID ILD) is a critical sequelae yet the role of immunomodulatory therapies remains unclear. We explored to characterize post-COVID ILD…
Abstract Number: 0309 • ACR Convergence 2024
Characteristics and Factors Associated with Treatment Response Among Patients with Eosinophilic Fasciitis: A Systematic Review and Meta-analysis
Omar Hamdan¹, Roa'a Alshajrawi¹, Qais Mussa¹, Yazeed Alajlouni¹, Yazan Dabbah¹, Rawan Fratekh¹, Yousef Al-Mabrouk², Shatha Al-Mabrok² and Ahmad A. Toubasi¹, ¹University of Jordan, Amman, Jordan, ²Mansoura University, Al Mansoura, Egypt
Background/Purpose: To date, data on the clinical features, diagnosis and the treatment of Eosinophilic Fasciitis (EF) patients are mostly derived from individual case reports, with…
Abstract Number: 0459 • ACR Convergence 2024
Tocilizumab Demonstrates Superior Inhibition of MMP-Mediated Basement Membrane Collagen Degradation Compared to Methotrexate or Placebo
Dovile Sinkeviciute¹, Sofie Falkenloeve Madsen², Nicolas Willumsen³, Patryk Drobinski³, Morten Karsdal³ and Anne-Christine Bay-Jensen³, ¹Nordic Bioscience, Herlev, Hovedstaden, Denmark, ²University of Copenhagen, Copenhagen N, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) pathogenesis involves a range of immune cells, for instance T-cells, neutrophils and macrophages. They produce proinflammatory factors, such as proteolytic enzymes,…
Abstract Number: 0693 • ACR Convergence 2024
Behind the Bronchiectasis in Systemic Sclerosis. Prevalence and Risk Factors
Miriam Retuerto Guerrero¹, Clara Moriano², Paula Perez Garcia³, cristiana sieiro santos⁴ and elvira Diez álvarez³, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain
Background/Purpose: Bronchiectasis (BC) has been observed in association with Systemic Sclerosis (SSc). Esophageal dysmotility, immunosuppressive drugs and the direct effect of collagen deposition in the…
Abstract Number: 0839 • ACR Convergence 2024
Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity
Haoyu Pan, Xiaohan Wei, Jinyi Qian, Shuyi Yu, Zhixia Yang, Zetao Ding, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized with the presence of pathogenic antiphospholipid antibodies (aPL) by autoreactive B cells. However, it remains…
Abstract Number: 0911 • ACR Convergence 2024
Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants
David Murphy, Yao Fu, Jennifer Kelly, Richard Pelikan, Graham Wiley and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Although millions of disease-associated variants have been discovered using GWAS, most of these occur in non-coding regions and their mechanistic link to disease is…
Abstract Number: 1002 • ACR Convergence 2024
Depression Screening in Patients with Rheumatologic Diseases in a Large Tertiary Care Center
Sama Hajizadeh¹, Yue Yin² and Adam Dore¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh
Background/Purpose: Depression is common and known to be associated with poorer outcomes among patients with rheumatologic diseases, likely stemming from the chronic and sometimes debilitating…
Abstract Number: 1151 • ACR Convergence 2024
Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy
Beibei Cui¹, Hongjiang Liu², Geng Yin³ and Qibing Xie⁴, ¹Rheumatology and Immunology, Chengdu, China (People's Republic), ²West China Hospital, Sichuan University, Chengdu, China (People's Republic), ³Department of Rheumatology and Immunology, chengdu, China (People's Republic), ⁴Department of Rheumatology and Immunology, Chengdu, Sichuan, China
Background/Purpose: The primary objective of this study was to comprehensively analyze the clinical characteristics of immune-mediated necrotizing myopathy (IMNM) and develop a reliable recurrence prediction…
Abstract Number: 1425 • ACR Convergence 2024
Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic
Sonia Jiménez Barrios¹, Sandra Garrote Corral², Juan Rigual³, Carlos de La Puente Bujidos³, Maria Angeles Blazquez Canamero⁴ and Jesús Loarce³, ¹Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Madrid, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴Hospital Ramon y Cajal, Madrid, Madrid, Spain
Background/Purpose: Pulmonary lung disease represents the most prevalent extra-glandular manifestation in patients with Sjögren’s syndrome (SS). Notably, interstitial lung disease (ILD) stands out as the…
Abstract Number: 1617 • ACR Convergence 2024
Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
Luigi Boiardi¹, Pierluigi Macchioni¹, Francesco Muratore², Chiara Marvisi¹, Caterina Ricordi¹, Annibale Versari¹, Giulia Besutti¹, Lucia Spaggiari¹, Stefania Croci¹ and Carlo Salvarani¹, ¹Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, ²Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
Abstract Number: 1750 • ACR Convergence 2024
Safety and Preliminary Efficacy of CD19 CAR-T Cell Treatment in Rheumatic Disease – Data from the First Part of the Phase I/II CASTLE Basket Study
Georg Schett¹, Fabian Müller², Melanie Hagen³, Andreas Wirsching³, Daniela Bohr⁴, Christina Bergmann⁵, Carlo Tur³, Simon Völkl⁶, Michael Aigner⁷, Sascha Kretschmann⁷, Silvia Spoerl⁷, Soraya Kharboutli⁷, Ingrid Vasova⁷, Daniel Aletaha⁸, Hans Kiener⁹, Gerlando Natalello¹⁰, Franco Locatelli¹¹, Maria Antonietta D´Agostino¹², Aline Bozec³, Ricardo Grieshaber-Bouyer¹³ and Andreas MAckensen¹⁴, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁶Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁷Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ⁹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ¹⁰Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ¹¹IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ¹²Catholic University of Sacred Heart, Rome, Italy, Rome, Italy, ¹³Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹⁴Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany
Background/Purpose: Systemic autoimmune diseases are based on an aberrant activation of B cells. Autologous CD19 chimeric antigen receptor (CAR) T cells allow deep depletion of…
Abstract Number: 1838 • ACR Convergence 2024
M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases
Michelle Downing¹, Ling Zhang¹, Aditee Desphpande¹, Hong Zhang¹, Ohad Tarcic², Mira toister-achituv², Alec Gross³, Gang Chen³ and Chia Chi Sun¹, ¹EMD Serono Research and Development Institute, Inc., Billerica, MA, ²Inter-lab Ltd, Merck KGaA, Yavne, Israel, ³EMD Serono Reserch and Development Institute, Inc, Billerica, MA
Background/Purpose: Overactive adaptive immune responses contribute to many autoimmune diseases such as systemic lupus erythematosus (SLE). Chronically activated autoreactive T-effector cells play a pivotal role…
Abstract Number: 1930 • ACR Convergence 2024
Clinical Significance of Positive ENA Testing in ANA-Negative Patients: A Retrospective Analysis of Rheumatologic Diagnoses
Bassel Bou Dargham¹, Jason Huang² and Michael Luggen³, ¹University of Cincinnati Medical Center, Cincinnati, OH, ²University of Cincinnati, Cincinnati, ³University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: On the basis of consensus methodology and literature review, the ACR has recommended that antibodies to extractable nuclear antigens (ENA), also known as subserologies…
Abstract Number: 2065 • ACR Convergence 2024
Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)
Samantha Coss¹, Danlei Zhou¹, Rabheh Abdul Aziz², Katherine Miller³, Shoghik Akoghlanian⁴, Kyla Driest¹, Edward Oberle¹, Vidya Sivaraman⁵, Charles Spencer⁶, Stacy Ardoin¹ and Chack-Yung Yu⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²University at Buffalo, Buffalo, NY, ³Nationwide Children's Hospital, Institute for Genomic Medicine, Columbus, OH, ⁴Nationwide Children�s Hospital, Columbus, OH, ⁵Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁶University of Mississippi Medical Center, Jackson, MS, ⁷Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, OH
Background/Purpose: JDM is an autoimmune disease of skin and muscle. We investigated genetic factors, autoantibodies, and clinical features in JDM.Methods: Subjects came from 2 large…

« Previous Page
1
…
3
4
5
6
7
…
80
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].